This reference uses the specific documents linked in the article and listed below. Check their scope, publication dates and the statements they support.
PSSM1 has a defined mechanism that should not be generalized to PSSM2
In PSSM1, a variant in the glycogen synthase gene alters the way muscle stores carbohydrate. One copy can confer disease susceptibility, with variable clinical expression. The established DNA test can therefore contribute meaningfully to diagnosis and breeding decisions. A positive result should be interpreted with the horse’s clinical state rather than used to predict an identical severity in every carrier.
PSSM2 refers to horses without the PSSM1 variant that have particular muscle-biopsy findings. It is not one fully resolved genetic disease, and some cases, particularly in certain performance-horse groups, have been reclassified through additional muscle assessment. A negative GYS1 test excludes that tested PSSM1 variant, not every possible cause of muscle stiffness or poor performance.
Source: Polysaccharide storage myopathy: PSSM1; Exertional myopathies in horses; Commercial genetic testing for type 2 polysaccharide storage myopathy and myofibrillar myopathy does not correspond to a histopathological diagnosis.
Clinical signs range from subtle intolerance to severe muscle injury
A horse may become stiff, sweat disproportionately, develop trembling or firm painful hindquarter muscles and refuse to move. Some episodes resemble colic because the horse paws, adopts an unusual stance or appears distressed. Others have chronic weakness or muscle loss rather than dramatic episodes.
Stop exercise and contact the veterinarian if tying up is suspected. Do not walk the horse until it loosens up or force it back toward the stable over a long distance. Dark urine, recumbency, marked weakness or severe pain is especially urgent because extensive muscle injury can affect circulation and kidneys. A breed associated with PSSM increases suspicion but does not establish the cause of an individual episode.
Source: Exertional myopathies in horses; Tying-up in horses.
Muscle enzymes measure injury, not the whole diagnosis
Blood creatine kinase and other muscle-associated enzymes help demonstrate and follow muscle damage. Their timing matters, and normal or modest concentrations between episodes do not exclude every chronic myopathy. A marked increase confirms a tissue process requiring investigation, not automatically PSSM rather than RER, toxin exposure or another disorder.
The veterinarian combines examination, diet and exercise history, appropriate genetic testing and sometimes biopsy. Biopsy interpretation requires expertise and the clinical context. The most useful question is whether the result explains the horse’s actual problem and changes management, not whether an isolated microscopic finding can be assigned a dramatic label.
Source: Exertional myopathies in horses; Recurrent exertional rhabdomyolysis; Clinical and histopathological features of myofibrillar myopathy in Warmblood horses.
Validated DNA testing is different from an unvalidated panel
The PSSM1 GYS1 test has a defined scientific basis. In contrast, a primary study found no significant association between the investigated commercial P2, P3 and P4 variants and biopsy-defined PSSM2 or MFM in the populations studied. BEVA advises against using unvalidated panels for clinical or life decisions.
This does not deny that a horse may have genuine muscle disease. It means the proposed genetic explanation must be demonstrated rather than assumed. Do not retire, breed, sell or euthanize a horse solely because an unvalidated panel reports a variant. Ask which clinical phenotype, validation evidence and limitations support the interpretation of each result.
Source: Commercial genetic testing for type 2 polysaccharide storage myopathy and myofibrillar myopathy does not correspond to a histopathological diagnosis; BEVA warns against the use of unvalidated genetic tests for PSSM2, MFM and MIM; Polysaccharide storage myopathy: PSSM1.
The long-term ration must fit the diagnosis and energy need
PSSM1 management commonly reduces starch and adjusts energy sources while ensuring adequate forage and a balanced ration. Fat may replace some calories when additional energy is needed, but adding energy indiscriminately can make an already overweight horse heavier. The full diet, body condition, workload and any endocrine disease influence the plan.
Do not assume that every horse labeled PSSM2 or MFM requires exactly the same diet as a PSSM1 horse. Evidence and response differ among these groups. A veterinarian or qualified equine nutritionist should help identify a practical ration and reassess comfort, condition and function, rather than rely on a proprietary supplement as a cure.
Source: Exertional myopathies in horses; Polysaccharide storage myopathy: PSSM1; BEVA warns against the use of unvalidated genetic tests for PSSM2, MFM and MIM; Clinical and histopathological features of myofibrillar myopathy in Warmblood horses.
Exercise management changes between an acute episode and prevention
During acute painful muscle injury, forced exercise is inappropriate. After assessment and stabilization, a planned gradual return to regular activity can be central to long-term management in many PSSM horses. Repeated prolonged rest followed by sudden work can be counterproductive in susceptible individuals.
The transition should follow the examined horse’s symptoms, muscle-enzyme pattern and veterinary advice rather than a universal number of days. Some horses maintain useful function with consistent management, while others remain limited. Breeding decisions for confirmed PSSM1 should use the validated inheritance information; uncertain PSSM2 variant results require a different level of caution and should not acquire certainty through repetition.
Source: Exertional myopathies in horses; Polysaccharide storage myopathy: PSSM1; Commercial genetic testing for type 2 polysaccharide storage myopathy and myofibrillar myopathy does not correspond to a histopathological diagnosis.
Practical questions
Does a negative PSSM1 test rule out muscle disease?
No. It excludes the tested GYS1 variant, not RER, MFM, biopsy-defined PSSM2 or other causes.
Should I walk a horse through tying up?
No. Stop exercise and obtain veterinary advice. Forced movement can add to muscle injury.
Does a P2/P3/P4 result prove PSSM2?
No. The cited validation evidence does not support treating those variants as diagnostic of the investigated biopsy-defined conditions.
Related animal-health reading
Cite this reference
LivestockDefense. “Polysaccharide storage myopathy in horses: PSSM1, PSSM2 and tying up.” Updated 2026-11-02. https://livestockdefense.com/threats/equine-polysaccharide-storage-myopathy/
Add the date you accessed the page. This identifies the current reference; keep a permitted saved copy if your work depends on its exact wording. A citation alone does not establish support for a claim.
How to cite a page and its revision ↗Sources & boundaries
Read the evidence in context.
These documents support the statements identified in this reference. Check their scope and dates when deciding whether they answer your question.
- Merck Veterinary Manual: Exertional Myopathies in Horses
Source update: Not provided. Most recent check: 2026-10-29.
Exertional myopathy is a syndrome with distinct possible causes; an historical symptom label does not establish a modern specific diagnosis. No genetic method, test protocol, exercise challenge or treatment supplied. Publisher page and indexed publisher text inspected.
- University of Minnesota College of Veterinary Medicine: Recurrent exertional rhabdomyolysis
Source update: Not provided. Most recent check: 2026-11-02.
RER muscle injury phenotype, clinical diagnosis and distinction from GYS1 PSSM1; research context does not establish an available validated RER DNA test.
- Rutgers Cooperative Extension: Tying-up in horses
Source update: Not provided. Most recent check: 2026-11-02.
Clinical differences between sporadic, recurrent, toxic and other muscle injury, acute stopping of exercise and long-term management categories; no home medication protocol.
- UC Davis Veterinary Genetics Laboratory: Polysaccharide storage myopathy: PSSM1
Source update: Not provided. Most recent check: 2026-11-02.
Validated GYS1 variant, dominant inheritance with variable expression, distinction from other myopathies; genetic sampling instructions and commercial prices not reproduced.
- Equine Veterinary Journal / primary clinical-pathology study: Clinical and histopathological features of myofibrillar myopathy in Warmblood horses
Source update: 2017. Most recent check: 2026-11-02.
Selected cases with desmin aggregates/myofibrillar pathology, clinical exercise intolerance and small uncontrolled management follow-up; not a universal causal gene or dietary cure claim.
- Equine Veterinary Journal / primary validation study: Commercial genetic testing for type 2 polysaccharide storage myopathy and myofibrillar myopathy does not correspond to a histopathological diagnosis
Source update: 2021. Most recent check: 2026-11-02.
No significant association of studied P2/P3/P4 variants with biopsy phenotype in the investigated Warmblood/Arabian populations; not a claim that clinical muscle disease is imaginary.
- British Equine Veterinary Association: BEVA warns against the use of unvalidated genetic tests for PSSM2, MFM and MIM
Source update: Not provided. Most recent check: 2026-11-02.
Professional association diagnostic-evidence position: no clinical, breeding or life decision based on unvalidated panels; keep PSSM1 validated testing distinct.
